YS Biopharma Co, News

YSDelisted Stock   0.48  0.03  5.88%   
Slightly above 62% of YS Biopharma's investor base is looking to short. The analysis of current outlook of investing in YS Biopharma Co, suggests that many traders are alarmed regarding YS Biopharma's prospects. YS Biopharma's investing sentiment can be driven by a variety of factors including economic data, YS Biopharma's earnings reports, geopolitical events, and overall market trends.
  
over six months ago at seekingalpha.com         
YS Biopharma reports 9M results
seekingalpha News
over six months ago at kalkinemedia.com         
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
news
over six months ago at investing.com         
YS Biopharmas new HBV vaccine enters Phase I trials
Investing News at Macroaxis
over six months ago at news.google.com         
YS Biopharma Set to Announce Quarterly Earnings on Friday - MarketBeat
Google News at Macroaxis
over six months ago at kalkinemedia.com         
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
news
over six months ago at finance.yahoo.com         
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vac...
Yahoo News
over six months ago at investing.com         
YS Biopharma reports progress in rabies vaccine trial
Investing News at Macroaxis
over six months ago at benzinga.com         
Chinese Biotech YS Biopharmas Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor
benzinga news
over six months ago at finance.yahoo.com         
Chinese Biotech YS Biopharmas Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor
Yahoo News
over six months ago at finance.yahoo.com         
YS Biopharma Announces Full Repayment of US40,000,000 Loan Facility
Yahoo News
over six months ago at seekingalpha.com         
YS Biopharma announces full repayment of 40M loan facility
seekingalpha News
over six months ago at investing.com         
YS Biopharma Announces Full Repayment of US40,000,000 Loan Facility
Investing News at Macroaxis
over six months ago at kalkinemedia.com         
YS Biopharma Announces Full Repayment of US40,000,000 Loan Facility
news
over six months ago at finance.yahoo.com         
YS Biopharma Announces Full Repayment of US40,000,000 Loan Facility
Yahoo News
over six months ago at news.google.com         
Short Interest in YS Biopharma Co., Ltd. Declines By 51.6 percent - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about YS Biopharma that are available to investors today. That information is available publicly through YS Biopharma media outlets and privately through word of mouth or via YS Biopharma internal channels. However, regardless of the origin, that massive amount of YS Biopharma data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of YS Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of YS Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to YS Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive YS Biopharma alpha.

YS Biopharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
YS Biopharma appoints Dave Chenn as interim CEO
05/07/2024
2
YS Biopharma to change legal name to LakeShore Biopharma
05/24/2024
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Consideration for investing in YS Biopharma Stock

If you are still planning to invest in YS Biopharma Co, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
CEOs Directory
Screen CEOs from public companies around the world
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios